Misconduct in Chinese Trials, Outcomes for BMS, Pfizer

Jul 12, 2013, 09:00 by Michael Croft
In the Pipeline | Bloomberg is reporting that a Bristol-Myers Squibb and Pfizer product approved last year was slowed by misconduct in its Chinese clinical trials.
July 12, 2013 | Bloomberg is reporting that a Bristol-Myers Squibb and Pfizer product approved last year was slowed by misconduct in its Chinese clinical trials. Derek Lowe breaks down the story and what it means for Chinese clinical trials. In the Pipeline